ArticleJournal of clinical laboratory analysis2026
Predictive Role of Hematological Biomarkers in Chronic Kidney Disease Progression.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammation and Erythropoietin Resistance in Chronic Kidney Disease: A Cross-Sectional Study of C-Reactive Protein and Anemia in Hemodialysis Patients.Journal of clinical laboratory analysis · 2026Article
- Impact of Blood Donation Frequency on the Prevalence of Cardiovascular Risk Factors Among Donors.Global health, epidemiology and genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease is a progressive disorder of the body with high morbidity. Hematological biomarkers can predict CKD progression.
objectiveThis study examined the predictive role of hematological parameters among adult CKD patients.
methodsThe records of 120 adult patients with CKD were retrieved. CKD staging was according to KDIGO guidelines. Hematological parameters were hemoglobin, WBC, percentages of neutrophils and lymphocytes, NLR, platelet count, MCV, and RDW. Data were analyzed to assess associations between hematological markers and disease stage.
resultsMean age was 56.4 ± 13.2 years, with 56.7% being male. Prevalence was 65.0% for hypertension and 38.3% for diabetes mellitus. There was a significant decrease in hemoglobin with CKD stage (13.4 ± 1.1 g/dL in Stage 1 to 8.5 ± 1.7 g/dL in Stage 5, p < 0.001), while NLR and RDW increased progressively with CKD stage (NLR: 1.55 ± 0.48 to 4.12 ± 1.02; RDW: 13.1% ± 0.8% to 16.0% ± 1.6%, both p < 0.001). Anemia and raised NLR were more frequent in the advanced stages of CKD. Logistic regression analysis identified hemoglobin (OR = 0.69, 95% CI: 0.58-0.82, p < 0.001), RDW (OR = 1.78, 95% CI: 1.33-2.39, p = 0.002), and NLR (OR = 1.91, 95% CI: 1.35-2.72, p = 0.001) as independent predictors of advanced CKD. These simple and inexpensive biomarkers are particularly valuable in resource-limited settings.
conclusionHematological biomarkers, especially hemoglobin, NLR, and RDW, were effectively used to predict the progression of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.